PE20131084A1 - Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor nociceptivo - Google Patents

Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor nociceptivo

Info

Publication number
PE20131084A1
PE20131084A1 PE2013000187A PE2013000187A PE20131084A1 PE 20131084 A1 PE20131084 A1 PE 20131084A1 PE 2013000187 A PE2013000187 A PE 2013000187A PE 2013000187 A PE2013000187 A PE 2013000187A PE 20131084 A1 PE20131084 A1 PE 20131084A1
Authority
PE
Peru
Prior art keywords
spyro
pyrane
cyclohexan
indol
dihydro
Prior art date
Application number
PE2013000187A
Other languages
English (en)
Inventor
Nadja Gruning
Marc Schiller
Ingo Friedrich
Chris Kirby
Ashish Hemani
John Bothmer
Andreas Scholz
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45556332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20131084A1 publication Critical patent/PE20131084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA PARA ADMINISTRACION ORAL QUE CONTIENE UN COMPUESTO DE FORMULA (I), DONDE R ES H O CH3. SON COMPUESTOS FAVORITOS: (1r,4r)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA, (1r,4r)-6'-FLUORO-N-METIL-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA O UNA SAL DE LOS MISMOS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DEL DOLOR NOCICEPTIVO AGUDO O CRONICO
PE2013000187A 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor nociceptivo PE20131084A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37063410P 2010-08-04 2010-08-04
US37064310P 2010-08-04 2010-08-04
US37064810P 2010-08-04 2010-08-04
EP10008116 2010-08-04
EP10008115 2010-08-04
EP10008117 2010-08-04

Publications (1)

Publication Number Publication Date
PE20131084A1 true PE20131084A1 (es) 2013-10-10

Family

ID=45556332

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000186A PE20131096A1 (es) 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico
PE2013000187A PE20131084A1 (es) 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor nociceptivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2013000186A PE20131096A1 (es) 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico

Country Status (28)

Country Link
US (3) US20120034297A1 (es)
EP (3) EP3459533A1 (es)
JP (2) JP5792298B2 (es)
KR (2) KR20130137600A (es)
CN (2) CN103237545A (es)
AU (2) AU2011287955B2 (es)
BR (2) BR112013002734A2 (es)
CA (2) CA2805525C (es)
CL (2) CL2013000218A1 (es)
CO (2) CO6680626A2 (es)
DK (2) DK2600850T3 (es)
EC (2) ECSP13012422A (es)
ES (1) ES2675316T3 (es)
HR (2) HRP20180904T1 (es)
HU (1) HUE039328T2 (es)
IL (2) IL224154B (es)
LT (2) LT2600850T (es)
MX (2) MX354686B (es)
NZ (2) NZ605888A (es)
PE (2) PE20131096A1 (es)
PL (2) PL2600850T3 (es)
PT (1) PT2600851T (es)
RS (2) RS58017B1 (es)
RU (2) RU2631481C2 (es)
SI (2) SI2600851T1 (es)
TR (1) TR201808244T4 (es)
WO (2) WO2012016698A2 (es)
ZA (1) ZA201300655B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180904T1 (hr) 2010-08-04 2018-08-24 Grünenthal GmbH Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za liječenje neuropatske boli
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
DK3235821T3 (da) * 2011-07-08 2020-04-20 Gruenenthal Gmbh Krystallinsk (1r,4r)-6'-fluor-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexan-1,1'-pyran¬[3,4,b]indol]-4-amin
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
AU2013369649B2 (en) 2012-12-31 2018-07-26 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
KR102354582B1 (ko) * 2014-08-12 2022-01-24 삼성전자 주식회사 전자 장치의 동작 방법 및 장치
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
JP6673924B2 (ja) * 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
CN106278994B (zh) * 2015-05-26 2019-06-21 复旦大学 螺环化合物及其制备方法和用途
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017148595A1 (en) 2016-02-29 2017-09-08 Grünenthal GmbH Titration of cebranopadol
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
IT201700057899A1 (it) 2017-05-29 2018-11-29 Univ Degli Studi Di Camerino Co-attivatori dei recettori MOP e NOP nel trattamento della dipendenza da droghe e/o psicostimolanti
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2572125B (en) * 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
EP4568702A1 (en) 2022-08-12 2025-06-18 Jazz Pharmaceuticals Research UK Limited Oral solid dosage forms comprising cannabinoids
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
KR20250145673A (ko) 2023-02-15 2025-10-13 애드뉴리스 테라퓨틱스 인코포레이티드 통증 완화에 유용한 요법 및 조성물
WO2026035694A1 (en) 2024-08-05 2026-02-12 Adneuris Therapeutics, Inc. Cebranopadol useful for preventing or reducing opioid induced respiratory depression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
FR2782006B1 (fr) 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1195160B1 (en) 2000-10-05 2009-09-16 USV Ltd. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
ATE359827T1 (de) 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
WO2005062722A2 (en) 2003-11-21 2005-07-14 Sun Pharmaceutical Industries Limited Fexofenadine containing pharmaceutical formulation
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2558393A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MX2007006777A (es) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
AU2007304425B2 (en) * 2006-10-02 2013-12-05 Spepharma Ag Non-mucoadhesive film dosage forms
WO2009118173A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte spirocyclische cyclohexan-derivate
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
PL2600846T3 (pl) 2010-08-04 2016-05-31 Gruenenthal Gmbh Farmaceutyczna postać dawki zawierająca 6'-fluoro-(n-metylo- albo N,N-dimetylo-)-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4,b]indol]-4-aminę
HRP20180904T1 (hr) 2010-08-04 2018-08-24 Grünenthal GmbH Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za liječenje neuropatske boli
ES2553742T3 (es) 2010-08-04 2015-12-11 Grünenthal GmbH Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina

Also Published As

Publication number Publication date
PL2600850T3 (pl) 2019-06-28
AU2011287955B2 (en) 2015-07-09
EP2600850B1 (en) 2018-10-17
MX350154B (es) 2017-08-29
PT2600851T (pt) 2018-06-19
CO6670579A2 (es) 2013-05-15
PE20131096A1 (es) 2013-10-10
LT2600851T (lt) 2018-06-25
WO2012016697A3 (en) 2012-08-16
PL2600851T3 (pl) 2018-08-31
MX2013001345A (es) 2013-03-22
ES2675316T3 (es) 2018-07-10
NZ605887A (en) 2014-08-29
RU2013109135A (ru) 2014-09-10
MX2013001289A (es) 2013-03-22
JP2013532697A (ja) 2013-08-19
RS57344B1 (sr) 2018-08-31
SI2600851T1 (en) 2018-07-31
AU2011287954B2 (en) 2015-07-09
ZA201300655B (en) 2013-09-25
JP5792298B2 (ja) 2015-10-07
HRP20180904T1 (hr) 2018-08-24
US9289416B2 (en) 2016-03-22
CN103260610A (zh) 2013-08-21
WO2012016698A2 (en) 2012-02-09
BR112013002734A2 (pt) 2016-06-07
RU2013109137A (ru) 2014-09-10
CN103237545A (zh) 2013-08-07
HUE039328T2 (hu) 2018-12-28
SI2600850T1 (sl) 2018-12-31
NZ605888A (en) 2014-08-29
AU2011287955A1 (en) 2013-02-07
US10912763B2 (en) 2021-02-09
BR112013003677A2 (pt) 2016-09-06
US20150111939A1 (en) 2015-04-23
CA2805525A1 (en) 2012-02-09
EP2600851B1 (en) 2018-05-02
CL2013000218A1 (es) 2013-03-15
CA2805523C (en) 2018-06-12
EP2600851A2 (en) 2013-06-12
JP5792299B2 (ja) 2015-10-07
CA2805525C (en) 2018-10-09
ECSP13012423A (es) 2013-03-28
DK2600850T3 (en) 2018-12-03
AU2011287954A1 (en) 2013-01-31
WO2012016697A2 (en) 2012-02-09
IL224154B (en) 2018-10-31
IL224155A (en) 2017-05-29
LT2600850T (lt) 2018-12-10
KR20130097173A (ko) 2013-09-02
DK2600851T3 (en) 2018-06-25
EP2600850A2 (en) 2013-06-12
KR20130137600A (ko) 2013-12-17
CL2013000225A1 (es) 2013-04-01
US20160361294A1 (en) 2016-12-15
HRP20181856T1 (hr) 2018-12-28
CO6680626A2 (es) 2013-05-31
ECSP13012422A (es) 2013-03-28
JP2013532696A (ja) 2013-08-19
RU2631481C2 (ru) 2017-09-22
MX354686B (es) 2018-03-15
US20120034297A1 (en) 2012-02-09
RU2638818C2 (ru) 2017-12-15
RS58017B1 (sr) 2019-02-28
EP3459533A1 (en) 2019-03-27
CA2805523A1 (en) 2012-02-09
TR201808244T4 (tr) 2018-07-23
WO2012016698A3 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
PE20131096A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico
PE20131106A1 (es) Aucforma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina
CO6640316A2 (es) Forma de dosificación famaceutica que comprende 6´fluoro-(n-metil-o n,n.dimetil)-4-fenil-4´9-dhidro-3 h espiro[ciclohexan-1´1-pirano[3.4,b[indol]-4-amina
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
CR20190331A (es) UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CY1120525T1 (el) Κρυσταλλικη (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,b]ινδολ]-4-αμινη
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CY1119887T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΜΟΡΦΗ ΔΟΣΟΛΟΓΙΑΣ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 6'-ΦΘΟΡΟ-(Ν-ΜΕΘΥΛΟ- Ή Ν,Ν-ΔΙΜΕΘΥΛΟ-)-4-ΦΑΙΝΥΛΟ-4',9'-ΔΙΥΔΡΟ-3'Η-ΣΠΕΙΡΟ [ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b] ΙΝΔΟΛ]-4-ΑΜΙΝΗ
PE20141113A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
EA201400685A1 (ru) Твердые формы гидрохлорида (1r,4r)-6'-фтор-(n,n-диметил)-4-фенил-4',9'-дигидро-3'н-спиро-[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амина
EA201401268A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ (1r,4r)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'H-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН И ГАБАПЕНТИНОИД
EA201401265A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и оксикам
EA201401272A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и парацетамол или пропацетамол
EA201400857A1 (ru) (1R,4R)-6'-ФТОР-(N-МЕТИЛ- ИЛИ N,N-ДИМЕТИЛ)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ И СИНДРОМА ХРОНИЧЕСКОЙ УСТАЛОСТИ
UA33293U (ru) Способ лечения хронического эндометрита
CY1116996T1 (el) Φαρμακευτικη δοσολογικη μορφη που περιεχει 6'-φθορο-(ν-μεθυλο- ή ν,ν-διμεθυλο-)-4-φαινυλο-4',9',-διυδρο-3'η-σπιρο[κυκλοεξαν-1,1'-πυρανο[3,4-β]ινδολ]-4-αμινη
CY1117385T1 (el) Φαρμακευτικη μορφη δοσολογιας περιλαμβανουσα 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4΄,9'-διϋδρο-3ή-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη
CY1120970T1 (el) Φαρμακευτικη μορφη δοσολογιας που περιλαμβανει 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4',9'-διυδρο-3ή-σπeipo[kykλoeξano-1,1'-πυρano[3,4,b]inδoλ]-4-aminh για την αγωγη του αλγαισθητικου πονου

Legal Events

Date Code Title Description
FC Refusal